EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Pleuropneumonectomy in the treatment of malignant pleural mesothelioma


Chest 116(6 Suppl): 450s-454s
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is predominantly a local/regional disease that results in a survival time that ranges from 4 to 12 months without treatment. Single-modality therapy using surgery, chemotherapy, or radiotherapy alone is largely ineffective. The objective of the study was presentation of the use of pleuropneumonectomy in a multimodality treatment setting and the results. Didactic presentation. Academic tertiary-care hospital. One hundred eighty-three patients who underwent multimodality therapy. Of all the single-modality treatment approaches, pleuropneumonectomy has been associated most consistently with long-term disease-free survival and has provided the greatest amount of tumor cytoreduction. The technique of pleuropneumonectomy traditionally has been linked with high perioperative mortality and morbidity when compared with that of other cytoreductive techniques such as pleurectomy/decortication. Recently, improvements in operative mortality (< 5%) have been reported, largely due to improvements in patient selection and perioperative management. Multimodality therapy, including chemotherapy, radiotherapy, and extrapleural pneumonectomy, was used to treat patients. Outcomes were presented for 183 patients with MPM who underwent multimodality therapy. With the development of multimodality therapy, pleuropneumonectomy followed by sequential chemotherapy and radiotherapy has demonstrated a significant survival benefit, especially for patients who have epithelial tumor histology, tumor-free resection margins, and tumor-free extrapleural node status.

(PDF 0-2 workdays service: $29.90)

Accession: 047002625

PMID: 10619506



Related references

Pleuropneumonectomy: an effective treatment modality for malignant pleural mesothelioma?. Annals of Thoracic and Cardiovascular Surgery 14(3): 135-137, 2008

What is the role of pleuropneumonectomy in malignant pleural mesothelioma?. Nihon Geka Gakkai Zasshi 110(6): 343-347, 2010

A case of diffuse pleural malignant mesothelioma treated with pleuropneumonectomy. Japanese Journal of Chest Diseases 47(5): 444-449, 1988

Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. International Journal of Radiation Oncology, Biology, Physics 78(2): 628-634, 2010

Intraoperative photodynamic therapy after pleuropneumonectomy for malignant pleural mesothelioma. Chest 122(5): 1866-7; Author Reply 1867, 2002

Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. International Journal of Radiation Oncology, Biology, Physics 69(5): 1593-1599, 2007

Reconstruction of the diaphragm with a pericardial flap after radical pleuropneumonectomy for malignant pleural mesothelioma. Thoraxchirurgie, Vaskulare Chirurgie 24(1): 1-5, 1976

Evaluation of the rehabilitation program in a patient submitted to pleuropneumonectomy for malignant pleural mesothelioma. Annali Italiani di Chirurgia 78(5): 397-400, 2008

Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma. Does finding and toxicity results. Chest 120(4): 1167-1174, October, 2001

Pleuropneumonectomy in the treatment of diffuse pleural mesothelioma. Archivio Monaldi Per la Tisiologia E le Malattie Dell'apparato Respiratorio 37(5-6): 311-318, 1982